Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with MASH and liver fibrosis.

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in obesity and knee osteoarthritis.

Recent studies reinforce that weight loss is not simply an esthetic consideration. It has very real benefits in terms of ...

A recent poll found that about 15.5 million Americans have used injectable diabetes medicines like Ozempic and Wegovy to lose ...

Thousands have injected themselves with compounded versions of the drug sold by pharmacies and 'med spas' amid nationwide ...

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.